Minimal Residual Disease Market

Market Overview:

The 7 major minimal residual disease markets reached a value of US$ 855.7 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2,261.0 Million by 2034, exhibiting a growth rate (CAGR) of 9.24% during 2024-2034.

The minimal residual disease market has been comprehensively analyzed in IMARC's new report titled "Minimal Residual Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Minimal residual disease (MRD) is a sub-microscopic disorder referring to the small number of cancer cells that remain in the body after initial treatment. These remaining cells in the body can become active and begin to multiply, which can lead to a relapse in the patients. There are typically no specific symptoms associated with this ailment due to the small number of unhealthy cells. The diagnosis of the condition is very challenging by conventionally employed cytogenetic and morphologic assessments. Hence, this illness can be detected through sensitive methods, such as multi-parametric flow cytometry and real-time quantitative polymerase chain reaction (PCR) assays, which can even determine very tiny amounts of cancer cells in the blood or bone marrow. The healthcare provider may perform MRD testing to monitor the effectiveness of the regimen and adjust the treatment plan if necessary. Other frequently utilized diagnostic procedures include computerized tomography (CT) scans and positron emission tomography (PET) scans.

The escalating cases of hematologic malignancies and the increased medical need to treat these diseases using radiotherapy and chemotherapy are primarily driving the minimal residual disease market. Moreover, the expanding geriatric population, who are prone to chronic health conditions on account of the weakened immune system, is also bolstering the market growth. In addition to this, the widespread adoption of intensive antineoplastic agents, including blinatumomab, imatinib, dasatinib, etc., to kill the residual tumor cells and enhance overall survival is acting as another significant growth-inducing factor. Furthermore, multiple key players are making extensive investments in R&D activities to introduce effective diagnostic tools with increased sensitivity, such as next-generation genetic sequencing, that can detect variations and other gene abnormalities. This, in turn, is also creating a positive outlook for the market. Additionally, the emerging popularity of targeted therapy, involving monoclonal antibodies, for treating the ailment since they can be engineered and designed to inhibit specific molecules that are necessary for cancer cell growth and survival, is further expected to drive the minimal residual disease market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the minimal residual disease market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for minimal residual disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the minimal residual disease market in any manner.

Recent Developments:

• In January 2024, Allogene Therapeutics Inc. and Foresight Diagnostics announced a strategic alliance to create a minimal residual disease in-vitro diagnostic (IVD) to evaluate eligibility in ALPHA3, the first pivotal study for first-line (1L) consolidation treatment of large B-cell lymphoma.
• In January 2024, Illumina Inc. stated that it had reached an agreement with Janssen Research & Development, LLC. This will be the first collaboration to develop Illumina's novel molecular residual disease assay, a whole-genome sequencing (WGS) multi-cancer research solution that recognizes circulating tumor DNA (ctDNA) to better understand disease persistence or recurrence after clinical intervention.

Key Highlights:

• Most studies define MRD positivity as the presence of 0.01% or more acute lymphoblastic leukemia (ALL) cells; the risk of relapse is often related to MRD level, especially when assessed after or at the conclusion of remission-induction therapy.
• The clinical importance of MRD has been firmly demonstrated in both childhood and adult ALL.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the minimal residual disease market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the minimal residual disease market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current minimal residual disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the minimal residual disease market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the minimal residual disease market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the minimal residual disease market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of minimal residual disease across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of minimal residual disease by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of minimal residual disease by gender across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of minimal residual disease by type across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with minimal residual disease across the seven major markets?
• What is the size of the minimal residual disease patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of minimal residual disease?
• What will be the growth rate of patients across the seven major markets?
   

Minimal Residual Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for minimal residual disease drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the minimal residual disease market?
• What are the key regulatory events related to the minimal residual disease market?
• What is the structure of clinical trial landscape by status related to the minimal residual disease market?
• What is the structure of clinical trial landscape by phase related to the minimal residual disease market?
• What is the structure of clinical trial landscape by route of administration related to the minimal residual disease market?